Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Sun Pharma and Mankind Pharma Shares Dip; Torrent Pharmaceuticals Gains Amid Quarterly Results

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Sun Pharma and Mankind Pharma Shares Dip; Torrent Pharmaceuticals Gains Amid Quarterly Results

Analysed 17 Aug 2026·3 sources analysed·Business
Sun Pharma and Mankind Pharma Shares Dip; Torrent Pharmaceuticals Gains Amid Quarterly ResultsPreviousNext

Shares of Sun Pharmaceutical Industries and Mankind Pharma declined by around 2% on August 17, 2026, while Torrent Pharmaceuticals' stock rose by 2%. All three companies reported growth in quarterly and annual revenues, with Sun Pharma and Torrent showing increased net profits. Mankind Pharma's annual net profit slightly decreased despite revenue growth. Corporate actions included dividend declarations by Sun Pharma and a new independent director appointment at Mankind Pharma. These movements reflect mixed market responses amid generally positive financial results.

Sentiment
54%
TBN's observations

First-hand measurement across 3 sources

We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (54/100). Lens Score 38/100.

Outlets measured: moneycontrol, moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 3 sources · Published under editorial oversight by The Balanced News
Analysed 17 Aug 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Neutral (54/100)

Sentiment was consistent across outlets (52–58/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

moneycontrol broke this story on 17 Aug, 07:45 am. Other outlets followed.

17 Aug, 07:45 am3 sources · 2 h17 Aug, 10:07 am
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
Festive Season Hiring to Create Up to 270,000 Gig Jobs Across India: Report
Next →
TCS Launches AI Platform to Enhance Drug Development and Clinical Trials
  1. 1
    moneycontrol17 Aug, 07:45 am
    Mankind Pharma shares fall over 2 to Rs 2,373.80- Moneycontrol.com
  2. 2
    moneycontrol17 Aug, 10:07 am
    Torrent Pharmaceuticals shares rise 2.01 to Rs 4,930- Moneycontrol.com
  3. 3
    moneycontrol17 Aug, 10:07 am
    Sun Pharmaceutical Industries shares fall 2.02 ; stock among top losers on Nifty 50- Moneycontrol.com

Who's involved

Institutions and figures named across source coverage.

Corporate
Mankind Pharma LimitedTorrent Pharmaceuticals LimitedSun Pharmaceutical Industries Limited

Story context

Category
Business
Sources analysed
3
Last analysed
17 Aug 2026
Key entities
CroreIndian rupeeEarnings per shareNet incomeNIFTY 50DividendStock splitSun PharmaPharmaceutical industryMarket trendRevenueAtorvastatin